)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Castle Biosciences
Castle Biosciences (CSTL) investor relations material
Castle Biosciences Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary6 May, 2026
Executive summary
Q1 2026 revenue was $83.7 million, with core test volumes up 36% year-over-year, driven by strong growth in DecisionDx-Melanoma and TissueCypher, despite a decline in dermatologic test revenues due to Medicare coverage loss for DecisionDx-SCC.
Full-year 2026 revenue guidance was raised to $345–$355 million, reflecting strong business momentum and increased confidence in top-line growth.
DecisionDx-Melanoma and TissueCypher tests delivered double-digit year-over-year volume growth, with record months in March 2026.
AdvanceAD-Tx test saw 650 orders in Q1, with positive clinician feedback and ongoing limited access rollout.
New clinical data validated DecisionDx-Melanoma's utility in risk stratification and biopsy decision-making, aligning with NCCN guidelines.
Financial highlights
Q1 2026 revenue was $83.7 million, down from $88.0 million in Q1 2025 due to changes in Medicare coverage and discontinued products.
Gross margin improved to 72.8% from 49.2% in Q1 2025; adjusted gross margin was 75.6%–76% vs. 81.2% prior year.
Net loss narrowed to $14.5 million from $25.8 million year-over-year; diluted loss per share improved to $0.49 from $0.90.
Adjusted EBITDA was negative $5.1 million, compared to $13 million in Q1 2025, reflecting prior year one-time amortization.
Cash, cash equivalents, and marketable securities totaled $261.7 million as of March 31, 2026.
Outlook and guidance
2026 revenue guidance raised to $345–$355 million, reflecting high teens to low 20% growth over 2025, excluding certain products.
Management expects continued investment in R&D and commercialization, with expenses projected to rise as new products are developed and launched.
Ongoing efforts to regain Medicare coverage for DecisionDx-SCC could impact future revenues.
AdvanceAD-Tx reimbursement clarity expected by end of Q3 2026; revenue to become material in 2027–2028.
Existing liquidity and anticipated cash from operations expected to fund operations for at least the next 12 months.
Novitas LCD impact on DecisionDx-SCC volume
Basis for the $33B AdvanceAD-Tx TAM estimate
i31-SLNB data and NCCN 5% threshold alignment
DecisionDx-SCC revenue impact from coverage change
Drivers of the $28.8M non-recurring cash outlay
TissueCypher impact on surveillance intervals
Explain the shift to non-dermatologic revenue
AdvanceAD-Tx order volume in limited launch
Update on the OIG healthcare claims subpoena
Explain the AdvanceAD-Tx reimbursement strategy
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Castle Biosciences
- Strong clinical evidence and financial growth support expansion and pipeline innovation.CSTL
Corporate presentation6 May 2026 - Genomic testing enables precise SLNB decisions and improved melanoma outcomes.CSTLStatus update29 Apr 2026
- 2025 saw record revenue, strong governance, and enhanced compensation and ESG policies.CSTLProxy filing8 Apr 2026
- Director elections, auditor ratification, and compensation policies up for vote at 2026 meeting.CSTLProxy filing8 Apr 2026
- 2025 revenue hit $344.2M with 37% core test growth and strong cash reserves.CSTLQ4 202526 Feb 2026
- Rapid TissueCypher adoption and strong Q3 results drive raised guidance and future growth.CSTLStephens 26th Annual Investment Conference | NASH20243 Feb 2026
- Strong growth in diagnostic testing, with expanding portfolio and positive reimbursement momentum.CSTLBaird Global Healthcare Conference 20253 Feb 2026
- Q2 revenue up 74% to $87M; 2024 guidance raised amid strong growth and robust cash position.CSTLQ2 20242 Feb 2026
- Expanding test adoption and sales force, with strong growth and plans to double melanoma penetration.CSTLCanaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026
Next Castle Biosciences earnings date
Q2 20263 Aug, 2026
Castle Biosciences
Next Castle Biosciences earnings date
Q2 20263 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage